DAT1 and BDNF polymorphisms interact to predict Aβ and tau pathology.

Area of Science:

• Neurogenetics
• Alzheimer's Disease Research
• Cognitive Neuroscience

Background:

• Dopamine transporter (DAT1/SLC6A3) and brain-derived neurotrophic factor (BDNF) gene polymorphisms have been linked to brain atrophy and memory decline.
• The precise relationship between these genetic variations and Alzheimer's disease (AD) pathology, such as beta-amyloid (Aβ) and tau accumulation, remains unclear.

Purpose of the Study:

• To investigate the effects of DAT1 and BDNF gene polymorphisms on AD pathology (Aβ and tau), hippocampal volume, and cognitive function.
• To explore potential interactions between DAT1 and BDNF in predicting AD-related biomarkers and atrophy.

Main Methods:

• Analysis of cross-sectional data from 321 cognitively normal older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
• Assessment of Aβ and tau pathology using positron emission tomography (PET) imaging.
• Measurement of hippocampal volume and cognitive performance.

Main Results:

• A significant interaction between DAT1 and BDNF polymorphisms was observed in predicting Aβ-PET, tau-PET, and hippocampal atrophy.
• Individuals carrying both the DAT1 C allele and the BDNF Met allele showed increased AD pathology and hippocampal atrophy.
• These findings suggest a combined genetic risk for AD pathology.

Conclusions:

• Novel links are established between dopamine and neurotrophic factor genes and the development of AD pathology.
• The interaction between DAT1 and BDNF variants may contribute to an elevated risk for Alzheimer's disease.
• These genetic factors could play a role in the early stages of AD pathogenesis.